IL6 and cancer: Accumulating evidence has indicated that IL-6, a target of let-7a, confers radioresistance to different types of cancers and that serum IL-6 levels can be used to predict treatment responses and outcomes for patients with esophageal squamous cell carcinoma [25–27, 30–32].